Glucagon-like peptide 2

被引：43
|
作者：
Drucker, DJ [1 ]
机构：
[1] Univ Toronto, Toronto Hosp, Banting & Best Diabet Ctr, Toronto, ON M5G 2C4, Canada
来源：
TRENDS IN ENDOCRINOLOGY AND METABOLISM | 1999年 / 10卷 / 04期
基金：
英国医学研究理事会;
关键词：
D O I：
10.1016/S1043-2760(98)00136-2
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Glucagon-like peptide 2 (GLP-2) is secreted in a nutrient-dependent manner from enteroendocrine cells throughout the gastrointestinal tract and is trophic to the intestinal epithelial mucosa. GLP-2 acts via stimulation of crypt cell proliferation and inhibition of cell death. GLP-2 also stimulates intestinal glucose transport, decreases mucosal permeability, and shows therapeutic efficacy in experimental models of short bowel syndrome and both small and large bowel inflammation.
引用
收藏
页码：153 / 156
页数：4
相关论文
共 50 条
  • [21] Glucagon-like peptide: The time is near
    Huang, A
    Raskin, P
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2004, 95 (06) : 249 - 251
  • [22] Glucagon-like peptide 1 and appetite
    Dailey, Megan J.
    Moran, Timothy H.
    TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2013, 24 (02): : 85 - 91
  • [23] GLUCAGON-LIKE PEPTIDE - A THERAPEUTIC GLIMMER
    AMIEL, SA
    LANCET, 1994, 343 (8888): : 4 - 5
  • [24] The discovery of glucagon-like peptide 1
    Lund, PK
    REGULATORY PEPTIDES, 2005, 128 (02) : 93 - 96
  • [25] Glucagon and glucagon-like peptide receptors as drug targets
    Estall, J. L.
    Drucker, D. J.
    CURRENT PHARMACEUTICAL DESIGN, 2006, 12 (14) : 1731 - 1750
  • [26] A kinetic study of glucagon-like peptide-1 and glucagon-like peptide-2 truncation by dipeptidyl peptidase IV, in vitro
    Lambeir, AM
    Proost, P
    Scharpé, S
    De Meester, I
    BIOCHEMICAL PHARMACOLOGY, 2002, 64 (12) : 1753 - 1756
  • [27] Efficacy and safety of high-dose glucagon-like peptide-1, glucagon-like peptide-1/glucose-dependent insulinotropic peptide, and glucagon-like peptide-1/glucagon receptor agonists in type 2 diabetes
    De Block, Christophe E. M.
    Dirinck, Eveline
    Verhaegen, Ann
    Van Gaal, Luc F.
    DIABETES OBESITY & METABOLISM, 2022, 24 (05): : 788 - 805
  • [28] Different from Glucagon-Like Peptide-1, Glucagon-Like Peptide-2 Is Associated with Obesity and Postprandial Lipemia in Subjects with Diabetes
    Takata, Yasunori
    Kawamura, Ryoichi
    Onuma, Hiroshi
    Osawa, Haruhiko
    DIABETES, 2015, 64 : A177 - A177
  • [29] Glucagon-like peptide 2 inhibits ghrelin secretion in humans
    Bulut, Kerem
    Banasch, Matthias
    Hagemann, Dirk
    Schrader, Henning
    Holst, Jens J.
    Schmidt, Wolfgang E.
    Meier, Juris J.
    REGULATORY PEPTIDES, 2006, 135 (03) : 119 - 119
  • [30] Evolution and therapeutic potential of glucagon-like peptide 2 analogs
    Gong, Binbin
    Wang, Ting
    Sun, Lidan
    BIOCHEMICAL PHARMACOLOGY, 2025, 233
12345